Drug Sponsors

Allergan, Molecular Partners form two exclusive alliances in eye disease

Tuesday, August 21, 2012 10:24 AM

Allergan, a multi-specialty health care company based in Medford, Mass., and Molecular Partners, a privately-owned Swiss biotech focused on a class of biological drugs known as DARPins, have significantly expanded their existing relationship by entering into two separate agreements to discover, develop and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

More... »

Shire joins ABPI

Tuesday, August 21, 2012 09:56 AM

Specialty biopharmaceutical company Shire has joined the Association of the British Pharmaceutical Industry (ABPI) as a full member.

More... »

Breast cancer drug market will be driven by 3 agents, says Decision Resources

Monday, August 20, 2012 02:18 PM

Three new breast cancer market entrants—Roche/Genentech’s Perjeta (pertuzumab) and trastuzumab-DM1 (T-DM1), and Novartis’s Afinitor (everolimus)—will drive growth in the breast cancer market through 2021, according to Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues.

More... »

Pharmacyclics triggers $50M milestone payment for mantle cell lymphoma trial

Monday, August 20, 2012 11:35 AM

Pharmacyclics, a clinical-stage biopharmaceutical company of Sunnyvale, Calif., announced that the clinical trial, SPARK, of ibrutinib in patients with relapsed or refractory mantle cell lymphoma (MCL) has enrolled its fifth patient, triggering a second $50 million milestone payment obligation from Janssen Biotech.

More... »

HUYA Bioscience, Tianjin Research Center form collaboration

Monday, August 20, 2012 10:03 AM

HUYA Bioscience International, focused on accelerating the global development of China’s pharmaceutical innovations, has formed a strategic partnership with Tianjin Research Center of Basic Medical Sciences (TJRCBMS), a nonprofit Chinese research institution.

More... »

Biogen Idec Foundation donates $100,000 to Teach for America STEM education

Monday, August 20, 2012 09:22 AM

The Biogen Idec Foundation andTeach For America have formed a new collaboration in support of Science, Technology, Engineering and Math (STEM) education.

More... »

Cinven to acquire Mercury Pharma

Friday, August 17, 2012 02:29 PM

Cinven, a European private equity firm, reached agreement to acquire Mercury Pharma, an international specialty pharmaceutical company, from owner HgCapital.

More... »

Biogen Idec, Regulus to explore microRNA biomarkers for monitoring MS

Friday, August 17, 2012 11:38 AM

Regulus Therapeutics, a San Diego-based biopharmaceutical company focused on medicines targeting microRNAs, has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis (MS).

More... »

Ark Therapeutics signs a letter of intent with EMD Millipore

Friday, August 17, 2012 11:13 AM

Ark Therapeutics, a London-based contract development and manufacturing company focused on viral product, has signed a non-binding letter of intent with EMD Millipore, a division of Merck, to enter into a collaborative agreement in the field of viral based bioengineered vaccines and other live viral products manufacturing. 

More... »

TG Therapeutics, Rhizen ink global agreement for TGR-1202

Friday, August 17, 2012 11:08 AM

TG Therapeutics, a clinical-stage biopharmaceutical company of New York, N.Y., and Rhizen Pharmaceuticals, a Switzerland-based biopharmaceutical company, have entered into an exclusive global agreement to collaborate on the development and commercialization of Rhizen's lead product candidate, TGR-1202, a novel PI3K delta inhibitor previously referred to as RP5264.

More... »